2017 Q2 Form 10-Q Financial Statement
#000119312517247437 Filed on August 03, 2017
Income Statement
| Concept | 2017 Q2 | 2016 Q2 |
|---|---|---|
| Revenue | $6.335M | $0.00 |
| YoY Change | ||
| Cost Of Revenue | $61.00K | $0.00 |
| YoY Change | ||
| Gross Profit | $6.274M | $0.00 |
| YoY Change | ||
| Gross Profit Margin | 99.04% | |
| Selling, General & Admin | $41.67M | $14.97M |
| YoY Change | 178.48% | 126.74% |
| % of Gross Profit | 664.23% | |
| Research & Development | $21.87M | $26.86M |
| YoY Change | -18.59% | 43.51% |
| % of Gross Profit | 348.55% | |
| Depreciation & Amortization | $600.0K | $300.0K |
| YoY Change | 100.0% | 0.0% |
| % of Gross Profit | 9.56% | |
| Operating Expenses | $63.60M | $41.83M |
| YoY Change | 52.06% | 65.18% |
| Operating Profit | -$57.27M | -$41.83M |
| YoY Change | 36.91% | 65.18% |
| Interest Expense | $4.767M | $0.00 |
| YoY Change | -100.0% | |
| % of Operating Profit | ||
| Other Income/Expense, Net | -$2.717M | $1.548M |
| YoY Change | -275.52% | 15.96% |
| Pretax Income | -$60.00M | -$40.30M |
| YoY Change | 48.88% | 67.92% |
| Income Tax | ||
| % Of Pretax Income | ||
| Net Earnings | -$59.99M | -$40.28M |
| YoY Change | 48.92% | 67.92% |
| Net Earnings / Revenue | -946.88% | |
| Basic Earnings Per Share | -$0.68 | |
| Diluted Earnings Per Share | -$0.68 | -$464.8K |
| COMMON SHARES | ||
| Basic Shares Outstanding | 88.06M | 86.66M shares |
| Diluted Shares Outstanding | 88.06M |
Balance Sheet
| Concept | 2017 Q2 | 2016 Q2 |
|---|---|---|
| SHORT-TERM ASSETS | ||
| Cash & Short-Term Investments | $525.0M | $387.4M |
| YoY Change | 35.52% | 0.7% |
| Cash & Equivalents | $309.5M | $86.25M |
| Short-Term Investments | $215.5M | $301.2M |
| Other Short-Term Assets | $5.529M | $4.568M |
| YoY Change | 21.04% | -2.73% |
| Inventory | $128.0K | |
| Prepaid Expenses | ||
| Receivables | $6.074M | |
| Other Receivables | $0.00 | |
| Total Short-Term Assets | $536.8M | $392.0M |
| YoY Change | 36.94% | 0.65% |
| LONG-TERM ASSETS | ||
| Property, Plant & Equipment | $6.954M | $5.811M |
| YoY Change | 19.67% | 107.39% |
| Goodwill | ||
| YoY Change | ||
| Intangibles | ||
| YoY Change | ||
| Long-Term Investments | $205.8M | $27.20M |
| YoY Change | 656.62% | -76.18% |
| Other Assets | $4.600M | $4.900M |
| YoY Change | -6.12% | 2.08% |
| Total Long-Term Assets | $217.3M | $37.87M |
| YoY Change | 473.87% | -68.9% |
| TOTAL ASSETS | ||
| Total Short-Term Assets | $536.8M | $392.0M |
| Total Long-Term Assets | $217.3M | $37.87M |
| Total Assets | $754.1M | $429.8M |
| YoY Change | 75.43% | -15.92% |
| SHORT-TERM LIABILITIES | ||
| YoY Change | ||
| Accounts Payable | $26.80M | $1.762M |
| YoY Change | 1421.0% | 70.24% |
| Accrued Expenses | $21.02M | |
| YoY Change | 69.6% | |
| Deferred Revenue | ||
| YoY Change | ||
| Short-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Long-Term Debt Due | ||
| YoY Change | ||
| Total Short-Term Liabilities | $27.72M | $26.90M |
| YoY Change | 3.06% | 53.24% |
| LONG-TERM LIABILITIES | ||
| Long-Term Debt | $360.7M | $0.00 |
| YoY Change | ||
| Other Long-Term Liabilities | $113.0K | $113.0K |
| YoY Change | 0.0% | -53.88% |
| Total Long-Term Liabilities | $113.0K | $113.0K |
| YoY Change | 0.0% | -53.88% |
| TOTAL LIABILITIES | ||
| Total Short-Term Liabilities | $27.72M | $26.90M |
| Total Long-Term Liabilities | $113.0K | $113.0K |
| Total Liabilities | $408.8M | $48.80M |
| YoY Change | 737.8% | 10.25% |
| SHAREHOLDERS EQUITY | ||
| Retained Earnings | -$1.195B | -$974.8M |
| YoY Change | 22.55% | 14.48% |
| Common Stock | $1.541B | $1.356B |
| YoY Change | 13.62% | 1576475.58% |
| Preferred Stock | ||
| YoY Change | ||
| Treasury Stock (at cost) | ||
| YoY Change | ||
| Treasury Stock Shares | ||
| Shareholders Equity | $345.2M | $381.0M |
| YoY Change | ||
| Total Liabilities & Shareholders Equity | $754.1M | $429.8M |
| YoY Change | 75.43% | -15.92% |
Cashflow Statement
| Concept | 2017 Q2 | 2016 Q2 |
|---|---|---|
| OPERATING ACTIVITIES | ||
| Net Income | -$59.99M | -$40.28M |
| YoY Change | 48.92% | 67.92% |
| Depreciation, Depletion And Amortization | $600.0K | $300.0K |
| YoY Change | 100.0% | 0.0% |
| Cash From Operating Activities | -$48.20M | -$14.30M |
| YoY Change | 237.06% | -202.14% |
| INVESTING ACTIVITIES | ||
| Capital Expenditures | -$400.0K | -$2.300M |
| YoY Change | -82.61% | 360.0% |
| Acquisitions | ||
| YoY Change | ||
| Other Investing Activities | -$212.4M | -$13.40M |
| YoY Change | 1485.07% | -74.91% |
| Cash From Investing Activities | -$212.8M | -$15.70M |
| YoY Change | 1255.41% | -70.87% |
| FINANCING ACTIVITIES | ||
| Cash Dividend Paid | ||
| YoY Change | ||
| Common Stock Issuance & Retirement, Net | ||
| YoY Change | ||
| Debt Paid & Issued, Net | ||
| YoY Change | ||
| Cash From Financing Activities | 506.5M | 900.0K |
| YoY Change | 56177.78% | -50.0% |
| NET CHANGE | ||
| Cash From Operating Activities | -48.20M | -14.30M |
| Cash From Investing Activities | -212.8M | -15.70M |
| Cash From Financing Activities | 506.5M | 900.0K |
| Net Change In Cash | 245.5M | -29.10M |
| YoY Change | -943.64% | -23.62% |
| FREE CASH FLOW | ||
| Cash From Operating Activities | -$48.20M | -$14.30M |
| Capital Expenditures | -$400.0K | -$2.300M |
| Free Cash Flow | -$47.80M | -$12.00M |
| YoY Change | 298.33% | -182.76% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2017Q3 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
88221674 | shares |
| CY2016Q1 | nbix |
Cease Use Liability
CeaseUseLiability
|
1043000 | |
| CY2016Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
86246000 | |
| CY2016Q2 | nbix |
Cease Use Liability
CeaseUseLiability
|
972000 | |
| CY2017Q1 | nbix |
Cease Use Liability
CeaseUseLiability
|
787000 | |
| CY2017Q2 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
| CY2017Q2 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
220000000 | shares |
| CY2017Q2 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
88216868 | shares |
| CY2017Q2 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2017Q2 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
88216868 | shares |
| CY2017Q2 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
| CY2017Q2 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
| CY2017Q2 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
5000000 | shares |
| CY2017Q2 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-1194635000 | |
| CY2017Q2 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
0 | |
| CY2017Q2 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
113000 | |
| CY2017Q2 | us-gaap |
Liabilities
Liabilities
|
408848000 | |
| CY2017Q2 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
754086000 | |
| CY2017Q2 | us-gaap |
Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
|
26809000 | |
| CY2017Q2 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
-713000 | |
| CY2017Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
345238000 | |
| CY2017Q2 | us-gaap |
Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
|
10231000 | |
| CY2017Q2 | us-gaap |
Debt Instrument Face Amount
DebtInstrumentFaceAmount
|
517500000 | |
| CY2017Q2 | us-gaap |
Common Stock Value
CommonStockValue
|
88000 | |
| CY2017Q2 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
1540498000 | |
| CY2017Q2 | us-gaap |
Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
|
1693000 | |
| CY2017Q2 | us-gaap |
Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
|
360681000 | |
| CY2017Q2 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
| CY2017Q2 | us-gaap |
Sale Leaseback Transaction Deferred Gain Net
SaleLeasebackTransactionDeferredGainNet
|
9100000 | |
| CY2017Q2 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
27721000 | |
| CY2017Q2 | us-gaap |
Deferred Rent Credit Current
DeferredRentCreditCurrent
|
0 | |
| CY2017Q2 | us-gaap |
Assets Current
AssetsCurrent
|
536751000 | |
| CY2017Q2 | us-gaap |
Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
|
389258000 | |
| CY2017Q2 | us-gaap |
Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
|
33000 | |
| CY2017Q2 | us-gaap |
Available For Sale Securities Continuous Unrealized Loss Position Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss
|
714000 | |
| CY2017Q2 | us-gaap |
Other Assets Current
OtherAssetsCurrent
|
5529000 | |
| CY2017Q2 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
6954000 | |
| CY2017Q2 | us-gaap |
Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
|
4613000 | |
| CY2017Q2 | us-gaap |
Security Deposit
SecurityDeposit
|
4700000 | |
| CY2017Q2 | us-gaap |
Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
|
215522000 | |
| CY2017Q2 | us-gaap |
Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
|
402006000 | |
| CY2017Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
309498000 | |
| CY2017Q2 | us-gaap |
Inventory Net
InventoryNet
|
128000 | |
| CY2017Q2 | us-gaap |
Investments
Investments
|
421300000 | |
| CY2017Q2 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
6074000 | |
| CY2017Q2 | us-gaap |
Available For Sale Securities Noncurrent
AvailableForSaleSecuritiesNoncurrent
|
205768000 | |
| CY2017Q2 | us-gaap |
Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
|
681000 | |
| CY2017Q2 | us-gaap |
Assets
Assets
|
754086000 | |
| CY2017Q2 | us-gaap |
Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue
|
12748000 | |
| CY2017Q2 | us-gaap |
Available For Sale Securities
AvailableForSaleSecurities
|
421290000 | |
| CY2017Q2 | us-gaap |
Debt Instrument Unamortized Discount Premium Net
DebtInstrumentUnamortizedDiscountPremiumNet
|
146523000 | |
| CY2017Q2 | us-gaap |
Deferred Finance Costs Net
DeferredFinanceCostsNet
|
10296000 | |
| CY2017Q2 | nbix |
Number Of Renewal Options
NumberOfRenewalOptions
|
2 | RenewalOptions |
| CY2017Q2 | nbix |
Letters Of Credit Collateral
LettersOfCreditCollateral
|
3000000 | |
| CY2017Q2 | nbix |
Deferred Gain On Sale Of Real Estate Current
DeferredGainOnSaleOfRealEstateCurrent
|
731000 | |
| CY2017Q2 | nbix |
Deferred Gain On Sale Of Real Estate Noncurrent
DeferredGainOnSaleOfRealEstateNoncurrent
|
8409000 | |
| CY2017Q2 | nbix |
Cease Use Liability Noncurrent
CeaseUseLiabilityNoncurrent
|
0 | |
| CY2017Q2 | nbix |
Cease Use Liability Current
CeaseUseLiabilityCurrent
|
181000 | |
| CY2017Q2 | nbix |
Cease Use Liability
CeaseUseLiability
|
181000 | |
| CY2008Q4 | us-gaap |
Sale Leaseback Transaction Deferred Gain Net
SaleLeasebackTransactionDeferredGainNet
|
39100000 | |
| CY2015Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
74195000 | |
| CY2015Q4 | nbix |
Cease Use Liability
CeaseUseLiability
|
1983000 | |
| CY2016Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
| CY2016Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
220000000 | shares |
| CY2016Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
86883300 | shares |
| CY2016Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2016Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
86883300 | shares |
| CY2016Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
| CY2016Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
| CY2016Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
5000000 | shares |
| CY2016Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-1056324000 | |
| CY2016Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
0 | |
| CY2016Q4 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
113000 | |
| CY2016Q4 | us-gaap |
Liabilities
Liabilities
|
50209000 | |
| CY2016Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
365086000 | |
| CY2016Q4 | us-gaap |
Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
|
26182000 | |
| CY2016Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
-318000 | |
| CY2016Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
314877000 | |
| CY2016Q4 | us-gaap |
Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
|
10231000 | |
| CY2016Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
87000 | |
| CY2016Q4 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
1371432000 | |
| CY2016Q4 | us-gaap |
Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
|
1462000 | |
| CY2016Q4 | us-gaap |
Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
|
0 | |
| CY2016Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
| CY2016Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
30414000 | |
| CY2016Q4 | us-gaap |
Deferred Rent Credit Current
DeferredRentCreditCurrent
|
470000 | |
| CY2016Q4 | us-gaap |
Assets Current
AssetsCurrent
|
310442000 | |
| CY2016Q4 | us-gaap |
Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
|
241956000 | |
| CY2016Q4 | us-gaap |
Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
|
3000 | |
| CY2016Q4 | us-gaap |
Available For Sale Securities Continuous Unrealized Loss Position Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss
|
324000 | |
| CY2016Q4 | us-gaap |
Other Assets Current
OtherAssetsCurrent
|
3092000 | |
| CY2016Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
6271000 | |
| CY2016Q4 | us-gaap |
Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
|
4883000 | |
| CY2016Q4 | us-gaap |
Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
|
224083000 | |
| CY2016Q4 | us-gaap |
Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
|
251100000 | |
| CY2016Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
83267000 | |
| CY2016Q4 | us-gaap |
Inventory Net
InventoryNet
|
0 | |
| CY2016Q4 | us-gaap |
Investments
Investments
|
267600000 | |
| CY2016Q4 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
0 | |
| CY2016Q4 | us-gaap |
Available For Sale Securities Noncurrent
AvailableForSaleSecuritiesNoncurrent
|
43490000 | |
| CY2016Q4 | us-gaap |
Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
|
321000 | |
| CY2016Q4 | us-gaap |
Assets
Assets
|
365086000 | |
| CY2016Q4 | us-gaap |
Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue
|
9144000 | |
| CY2016Q4 | us-gaap |
Available For Sale Securities
AvailableForSaleSecurities
|
267573000 | |
| CY2016Q4 | nbix |
Deferred Gain On Sale Of Real Estate Current
DeferredGainOnSaleOfRealEstateCurrent
|
3526000 | |
| CY2016Q4 | nbix |
Deferred Gain On Sale Of Real Estate Noncurrent
DeferredGainOnSaleOfRealEstateNoncurrent
|
7372000 | |
| CY2016Q4 | nbix |
Cease Use Liability Noncurrent
CeaseUseLiabilityNoncurrent
|
617000 | |
| CY2016Q4 | nbix |
Cease Use Liability Current
CeaseUseLiabilityCurrent
|
236000 | |
| CY2016Q4 | nbix |
Cease Use Liability
CeaseUseLiability
|
853000 | |
| us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
500000 | shares | |
| dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
Q2 | ||
| dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2017 | ||
| dei |
Document Type
DocumentType
|
10-Q | ||
| dei |
Entity Central Index Key
EntityCentralIndexKey
|
0000914475 | ||
| us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-125596000 | ||
| us-gaap |
Stock Issued During Period Shares Restricted Stock Award Gross
StockIssuedDuringPeriodSharesRestrictedStockAwardGross
|
300000 | shares | |
| dei |
Trading Symbol
TradingSymbol
|
NBIX | ||
| dei |
Amendment Flag
AmendmentFlag
|
false | ||
| us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
87675000 | shares | |
| dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | ||
| dei |
Document Period End Date
DocumentPeriodEndDate
|
2017-06-30 | ||
| dei |
Entity Filer Category
EntityFilerCategory
|
Large Accelerated Filer | ||
| us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
800000 | shares | |
| us-gaap |
Use Of Estimates
UseOfEstimates
|
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> <i>Use of Estimates</i>. The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and the accompanying notes. Actual results could differ from those estimates.</p> </div> | ||
| us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-1.58 | ||
| us-gaap |
Revenue Recognition Sales Of Goods
RevenueRecognitionSalesOfGoods
|
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> <b><i>Revenue Recognition Policy.</i></b> The Company’s net product sales consist of U.S. sales of INGREZZA and are recognized when (i) persuasive evidence of an arrangement exists, (ii) delivery has occurred and title to the product and associated risk of loss has passed to the customer, (iii) the price is fixed or determinable, and (iv) collectability is reasonably assured.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> INGREZZA was approved by the FDA on April 11, 2017 and the Company commenced shipments of INGREZZA to select pharmacies (SPs) and a select distributor (SD) in late April 2017. The SPs dispense product to a patient based on the fulfillment of a prescription and the SD sells product to government facilities, long-term care pharmacies <font style="WHITE-SPACE: nowrap">or in-patient</font> hospital pharmacies. The Company’s agreements with SPs and SDs provide for transfer of title to the product at the time the product is delivered to the SP or SD. In addition, except for limited circumstances, the SPs and SDs have no right of product return to the Company.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> The Company has determined it can reasonably estimate its allowances for rebates and chargebacks at the time title and risk of loss transfers to the SP or SD. Therefore, the Company records revenue when the product is delivered to the SPs or SD, which is an approach frequently referred to as the <font style="WHITE-SPACE: nowrap">“sell-in”</font> revenue recognition model.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> The Company recognizes revenue from product sales net of the following allowances:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> <i>Distribution Fees:</i> Distribution fees include fees paid to the SPs and SD for data and prompt payment discounts. Distribution fees are recorded as an offset to revenue based on contractual terms at the time revenue from the sale is recognized.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> <i>Rebates:</i> Rebates include mandated discounts under the Medicaid Drug Rebate Program and the Medicare Part D prescription drug benefit. Rebates are amounts owed after the final dispensing of the product to a benefit plan participant and are based upon contractual agreements with, or statutory requirements pertaining to, Medicaid and Medicare benefit providers. The allowance for rebates is based on statutory discount rates and expected utilization. The Company’s expected utilization of rebates is based on data received from the SPs and SD.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> <i>Chargebacks:</i> Chargebacks are discounts that relate to contracts with government and other entities purchasing from the SDs at a discounted price. The SD charges back to the Company the difference between the price initially paid by the SD and the discounted price paid to the SD by these entities. The Company allowance for chargebacks is based on known SD sales to contracted entities.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> <i><font style="WHITE-SPACE: nowrap">Co-Payment</font> Assistance:</i> The Company offers <font style="WHITE-SPACE: nowrap">co-payment</font> assistance to commercially insured patients meeting certain eligibility requirements. <font style="WHITE-SPACE: nowrap">Co-payment</font> assistance is recorded as an offset to gross revenue at the time revenue from the product sale is recognized based on expected and actual program participation.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> <i>Product Returns:</i> The Company offers the SPs and SD limited product return rights for damages and shipment errors provided it is within a very limited period after the original shipping date as set forth in the applicable individual distribution agreement. The Company does not allow product returns for product that has been dispensed to a patient or for drug expiration. The Company receives real-time shipping reports and inventory reports from the SPs and SD and has the ability to control the amount of product that is sold to the SPs and SD. It is also able to make a reasonable estimate of potential product returns due to the limited time-frame allowed for the SPs and SD to process returns due to shipment error or damaged product.</p> </div> | ||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
|
1600000 | shares | |
| us-gaap |
Revenues
Revenues
|
6335000 | ||
| us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
1759000 | ||
| us-gaap |
Investment Income Net
InvestmentIncomeNet
|
1896000 | ||
| dei |
Entity Registrant Name
EntityRegistrantName
|
NEUROCRINE BIOSCIENCES INC | ||
| us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
-596000 | ||
| us-gaap |
Sales Revenue Goods Net
SalesRevenueGoodsNet
|
6335000 | ||
| us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
-395000 | ||
| us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-137200000 | ||
| us-gaap |
Net Income Loss
NetIncomeLoss
|
-138311000 | ||
| us-gaap |
Interest Paid
InterestPaid
|
0 | ||
| us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
128000 | ||
| us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
6074000 | ||
| us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-138706000 | ||
| us-gaap |
Licenses Revenue
LicensesRevenue
|
0 | ||
| us-gaap |
Sale Leaseback Transaction Current Period Gain Recognized
SaleLeasebackTransactionCurrentPeriodGainRecognized
|
1800000 | ||
| us-gaap |
Payments To Acquire Investments
PaymentsToAcquireInvestments
|
365032000 | ||
| us-gaap |
Operating Leases Rent Expense Sublease Rentals1
OperatingLeasesRentExpenseSubleaseRentals1
|
600000 | ||
| us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-1111000 | ||
| us-gaap |
Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
|
-270000 | ||
| us-gaap |
Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
|
2437000 | ||
| us-gaap |
Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
|
1760000 | ||
| us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
18900000 | ||
| us-gaap |
Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
|
-239000 | ||
| us-gaap |
Interest Expense
InterestExpense
|
4767000 | ||
| us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
-156197000 | ||
| us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
5243000 | ||
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
18866000 | ||
| us-gaap |
Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
|
2651000 | ||
| us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
1078000 | ||
| us-gaap |
Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
|
0 | ||
| us-gaap |
Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
|
502781000 | ||
| us-gaap |
Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
|
210324000 | ||
| us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
69724000 | ||
| us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
508024000 | ||
| us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
73750000 | ||
| us-gaap |
Amortization Of Financing Costs
AmortizationOfFinancingCosts
|
207000 | ||
| us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
226231000 | ||
| us-gaap |
Cost Of Goods Sold
CostOfGoodsSold
|
61000 | ||
| us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
627000 | ||
| us-gaap |
Operating Expenses
OperatingExpenses
|
143535000 | ||
| us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
5200000 | ||
| nbix |
Deferred Gain On Sale Of Real Estate
DeferredGainOnSaleOfRealEstate
|
1758000 | ||
| nbix |
Lease Expiration Year
LeaseExpirationYear
|
2029 | ||
| nbix |
Nonoperating Gain Loss On Disposition Of Assets
NonoperatingGainLossOnDispositionOfAssets
|
2000 | ||
| nbix |
Subleased Agreement Area
SubleasedAgreementArea
|
16000 | sqft | |
| nbix |
Cease Use Liability Payment
CeaseUseLiabilityPayment
|
128000 | ||
| nbix |
Increase Decrease In Cease Use Expense
IncreaseDecreaseInCeaseUseExpense
|
-544000 | ||
| nbix |
Increase Decrease In Cease Use Liability
IncreaseDecreaseInCeaseUseLiability
|
-128000 | ||
| nbix |
Change In Estimate On Cease Use Liability
ChangeInEstimateOnCeaseUseLiability
|
-544000 | ||
| us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
300000 | shares | |
| us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-43546000 | ||
| us-gaap |
Stock Issued During Period Shares Restricted Stock Award Gross
StockIssuedDuringPeriodSharesRestrictedStockAwardGross
|
300000 | shares | |
| us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
86595000 | shares | |
| us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
200000 | shares | |
| us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.69 | ||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
|
900000 | shares | |
| us-gaap |
Revenues
Revenues
|
15000000 | ||
| us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
2984000 | ||
| us-gaap |
Investment Income Net
InvestmentIncomeNet
|
1417000 | ||
| us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
-2440000 | ||
| us-gaap |
Sales Revenue Goods Net
SalesRevenueGoodsNet
|
0 | ||
| us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
938000 | ||
| us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-62685000 | ||
| us-gaap |
Net Income Loss
NetIncomeLoss
|
-59544000 | ||
| us-gaap |
Interest Paid
InterestPaid
|
0 | ||
| us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
600000 | ||
| us-gaap |
Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
|
-108000 | ||
| us-gaap |
Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
|
227150000 | ||
| us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
26919000 | ||
| us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
0 | ||
| us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
0 | ||
| us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-58606000 | ||
| us-gaap |
Licenses Revenue
LicensesRevenue
|
15000000 | ||
| us-gaap |
Sale Leaseback Transaction Current Period Gain Recognized
SaleLeasebackTransactionCurrentPeriodGainRecognized
|
1700000 | ||
| us-gaap |
Payments To Acquire Investments
PaymentsToAcquireInvestments
|
169488000 | ||
| us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
3141000 | ||
| us-gaap |
Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
|
92000 | ||
| us-gaap |
Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
|
-315000 | ||
| us-gaap |
Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
|
1724000 | ||
| us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
14200000 | ||
| us-gaap |
Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
|
-136000 | ||
| us-gaap |
Interest Expense
InterestExpense
|
0 | ||
| us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
54599000 | ||
| us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
998000 | ||
| us-gaap |
Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
|
13000 | ||
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
14192000 | ||
| us-gaap |
Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
|
0 | ||
| us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
998000 | ||
| us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
50766000 | ||
| us-gaap |
Amortization Of Financing Costs
AmortizationOfFinancingCosts
|
0 | ||
| us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
12051000 | ||
| us-gaap |
Cost Of Goods Sold
CostOfGoodsSold
|
0 | ||
| us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
1184000 | ||
| us-gaap |
Operating Expenses
OperatingExpenses
|
77685000 | ||
| us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
1000000 | ||
| nbix |
Deferred Gain On Sale Of Real Estate
DeferredGainOnSaleOfRealEstate
|
1707000 | ||
| nbix |
Nonoperating Gain Loss On Disposition Of Assets
NonoperatingGainLossOnDispositionOfAssets
|
17000 | ||
| nbix |
Cease Use Liability Payment
CeaseUseLiabilityPayment
|
181000 | ||
| nbix |
Increase Decrease In Cease Use Expense
IncreaseDecreaseInCeaseUseExpense
|
-584000 | ||
| nbix |
Increase Decrease In Cease Use Liability
IncreaseDecreaseInCeaseUseLiability
|
-181000 | ||
| nbix |
Change In Estimate On Cease Use Liability
ChangeInEstimateOnCeaseUseLiability
|
-830000 | ||
| CY2007Q4 | us-gaap |
Mortgage Loans On Real Estate Cost Of Mortgages Sold
MortgageLoansOnRealEstateCostOfMortgagesSold
|
47700000 | |
| CY2007Q4 | us-gaap |
Sale Leaseback Transaction Net Proceeds Financing Activities
SaleLeasebackTransactionNetProceedsFinancingActivities
|
61000000 | |
| CY2007Q4 | us-gaap |
Sale Leaseback Transaction Gross Proceeds Investing Activities
SaleLeasebackTransactionGrossProceedsInvestingActivities
|
109000000 | |
| CY2007Q4 | nbix |
Number Of Buildings Leased
NumberOfBuildingsLeased
|
2 | Building |
| CY2007Q4 | nbix |
Sale Leaseback Transaction Lease Period
SaleLeasebackTransactionLeasePeriod
|
P12Y | |
| CY2016Q2 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
300000 | shares |
| CY2016Q2 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
86694000 | shares |
| CY2016Q2 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.46 | |
| CY2016Q2 | us-gaap |
Revenues
Revenues
|
0 | |
| CY2016Q2 | us-gaap |
Investment Income Net
InvestmentIncomeNet
|
680000 | |
| CY2016Q2 | us-gaap |
Sales Revenue Goods Net
SalesRevenueGoodsNet
|
0 | |
| CY2016Q2 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
149000 | |
| CY2016Q2 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-41828000 | |
| CY2016Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-40280000 | |
| CY2016Q2 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-40131000 | |
| CY2016Q2 | us-gaap |
Licenses Revenue
LicensesRevenue
|
0 | |
| CY2016Q2 | us-gaap |
Sale Leaseback Transaction Current Period Gain Recognized
SaleLeasebackTransactionCurrentPeriodGainRecognized
|
900000 | |
| CY2016Q2 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
1548000 | |
| CY2016Q2 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
7300000 | |
| CY2016Q2 | us-gaap |
Interest Expense
InterestExpense
|
0 | |
| CY2016Q2 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
14965000 | |
| CY2016Q2 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
26863000 | |
| CY2016Q2 | us-gaap |
Cost Of Goods Sold
CostOfGoodsSold
|
0 | |
| CY2016Q2 | us-gaap |
Operating Expenses
OperatingExpenses
|
41828000 | |
| CY2016Q2 | nbix |
Deferred Gain On Sale Of Real Estate
DeferredGainOnSaleOfRealEstate
|
854000 | |
| CY2016Q2 | nbix |
Nonoperating Gain Loss On Disposition Of Assets
NonoperatingGainLossOnDispositionOfAssets
|
14000 | |
| CY2016Q2 | nbix |
Cease Use Liability Payment
CeaseUseLiabilityPayment
|
71000 | |
| CY2016Q2 | nbix |
Change In Estimate On Cease Use Liability
ChangeInEstimateOnCeaseUseLiability
|
0 | |
| CY2017Q2 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
400000 | shares |
| CY2017Q2 | us-gaap |
Stock Issued During Period Shares Share Based Compensation Gross
StockIssuedDuringPeriodSharesShareBasedCompensationGross
|
200000 | shares |
| CY2017Q2 | us-gaap |
Property Management Fee Percent Fee
PropertyManagementFeePercentFee
|
0.035 | pure |
| CY2017Q2 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
88063000 | shares |
| CY2017Q2 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.68 | |
| CY2017Q2 | us-gaap |
Revenues
Revenues
|
6335000 | |
| CY2017Q2 | us-gaap |
Investment Income Net
InvestmentIncomeNet
|
1169000 | |
| CY2017Q2 | us-gaap |
Sales Revenue Goods Net
SalesRevenueGoodsNet
|
6335000 | |
| CY2017Q2 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
-478000 | |
| CY2017Q2 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-57268000 | |
| CY2017Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-59985000 | |
| CY2017Q2 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-60463000 | |
| CY2017Q2 | us-gaap |
Licenses Revenue
LicensesRevenue
|
0 | |
| CY2017Q2 | us-gaap |
Sale Leaseback Transaction Current Period Gain Recognized
SaleLeasebackTransactionCurrentPeriodGainRecognized
|
900000 | |
| CY2017Q2 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-2717000 | |
| CY2017Q2 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
9900000 | |
| CY2017Q2 | us-gaap |
Interest Expense
InterestExpense
|
4767000 | |
| CY2017Q2 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
41674000 | |
| CY2017Q2 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
21868000 | |
| CY2017Q2 | us-gaap |
Cost Of Goods Sold
CostOfGoodsSold
|
61000 | |
| CY2017Q2 | us-gaap |
Operating Expenses
OperatingExpenses
|
63603000 | |
| CY2017Q2 | nbix |
Deferred Gain On Sale Of Real Estate
DeferredGainOnSaleOfRealEstate
|
879000 | |
| CY2017Q2 | nbix |
Nonoperating Gain Loss On Disposition Of Assets
NonoperatingGainLossOnDispositionOfAssets
|
2000 | |
| CY2017Q2 | nbix |
Lease Extension Period
LeaseExtensionPeriod
|
P10Y | |
| CY2017Q2 | nbix |
Cease Use Liability Payment
CeaseUseLiabilityPayment
|
62000 | |
| CY2017Q2 | nbix |
Change In Estimate On Cease Use Liability
ChangeInEstimateOnCeaseUseLiability
|
-544000 |
